David Fredrickson

Executive Vice-President, Oncology Business Unit, AstraZeneca

Dave Fredrickson was appointed Executive Vice-President, Oncology Business Unit (OBU) in October 2017 and is responsible for driving growth and maximising the commercial performance of the AstraZeneca global oncology portfolio. In addition, Dave plays a critical leadership role defining and delivering the oncology strategy for the company with accountability for marketing, sales, medical affairs and market access both globally and in major markets. Dave serves as the executive lead for AstraZeneca’s North American Inclusion & Diversity strategy, as well as for the company’s Health Equity Advisory Council where he works with a diverse group of external experts to advance health equity in the U.S. Since joining AstraZeneca in 2014, Dave has held several leadership positions of increasing responsibility, including Vice President, Specialty Care for AstraZeneca in the U.S. and President of AstraZeneca K. K. in Japan. Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions, including Oncology Business Unit Manager in Spain and strategy, marketing and sales roles in the U.S. Before joining Roche/Genentech, Dave worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. Dave is a graduate of Georgetown University in Washington, DC.

最热内容

健康与医疗系统

1971任美国”。:“。”·第一。50年后...

2023年01月29日

关于我们

会议

媒体

合作伙伴和会员

  • 加入我们

语言版本

隐私政策和服务条款

© 2024 世界经济论坛